{"id":"tnf-inhibitor-w0-w12","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased infection risk (including tuberculosis, opportunistic infections)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Malignancy risk (lymphoma, solid tumors)"}]},"_chembl":{"chemblId":"CHEMBL3897557","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TNF is a pro-inflammatory cytokine central to inflammatory and autoimmune diseases. TNF inhibitors work by binding to and neutralizing TNF or blocking its receptors (TNFR1/TNFR2), thereby suppressing the inflammatory cascade. This reduces immune cell activation, cytokine production, and tissue inflammation in conditions driven by TNF overexpression.","oneSentence":"TNF inhibitors block tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce inflammation and immune-mediated tissue damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:39:07.527Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Inflammatory bowel disease (Crohn's disease, ulcerative colitis)"},{"name":"Ankylosing spondylitis"},{"name":"Psoriasis and psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT05428488","phase":"PHASE3","title":"Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2022-11-28","conditions":"Rheumatoid Arthritis","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TNF Inhibitor (W0-W12)","genericName":"TNF Inhibitor (W0-W12)","companyName":"University Hospital, Montpellier","companyId":"university-hospital-montpellier","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TNF inhibitors block tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce inflammation and immune-mediated tissue damage. Used for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease, ulcerative colitis), Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}